title: Hyperlipoprotein(a)aemia in nephrotic syndrome.
abstract: The nephrotic syndrome is frequently associated with hyperlipidaemia and hyperfibrinogenaemia, leading to an increased coronary and thrombotic risk, which may be enhanced by high lipoprotein (a) [Lp(a)] concentrations. We followed the quantitative and qualitative pattern of plasma lipoproteins over 18 months in a patient with nephrotic syndrome suffering from premature coronary artery disease and with elevated level of Lp(a) (470 mg dL-1). Analysis of kinetic parameters after heparin-induced extracorporeal plasma apheresis revealed a reduced fractional catabolic rate for both low-density lipoprotein (LDL) and Lp(a). After improvement of the nephrotic syndrome, Lp(a) decreased to 169 mg dL-1 and LDL concentrations were normalized. The decrease of Lp(a) was associated with an increase in plasma albumin concentrations. Analysis of apo(a) isoforms in the patient showed the presence of isoform S2 (alleles 10 and 19). Consequently, the authors' present strategy is to normalize the elevated Lp(a) and fibrinogen levels. For this purpose heparin-mediated extracorporeal LDL precipitation (HELP) apheresis is a promising regimen, helping to reduce the thrombotic risk and prevent coronary and graft atherosclerosis as well as the progression of glomerulosclerosis in our patient.
authors.affiliation: Institut für Klinische Chemie, Universitätsklinikum Grosshadern, Munich, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Thiery
authors.forename: B
authors.initials: B
authors.lastname: Ivandic
authors.forename: G
authors.initials: G
authors.lastname: Bahlmann
authors.forename: A K
authors.initials: AK
authors.lastname: Walli
authors.forename: D
authors.initials: D
authors.lastname: Seidel
mesh_terms: D000328:Adult; D001053:Apolipoproteins / Q000097:blood; D001798:Blood Proteins / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D003327:Coronary Disease / Q000097:blood; D004573:Electrolytes / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood* / Q000628:therapy; D017270:Lipoprotein(a) / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D009203:Myocardial Infarction / Q000097:blood* / Q000150:complications; D009404:Nephrotic Syndrome / Q000097:blood* / Q000150:complications / Q000628:therapy; D010956:Plasmapheresis; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D001053:Apolipoproteins; D001798:Blood Proteins; D004573:Electrolytes; D017270:Lipoprotein(a); D008074:Lipoproteins; D014280:Triglycerides; D002784:Cholesterol